These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 2444650)
41. Epitope-specific protective immunogenicity of chemically synthesized 13-, 18-, and 23-residue peptide fragments of streptococcal M protein. Beachey EH; Tartar A; Seyer JM; Chedid L Proc Natl Acad Sci U S A; 1984 Apr; 81(7):2203-7. PubMed ID: 6425829 [TBL] [Abstract][Full Text] [Related]
42. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. Beachey EH; Stollerman GH; Johnson RH; Ofek I; Bisno AL J Exp Med; 1979 Oct; 150(4):862-77. PubMed ID: 390084 [TBL] [Abstract][Full Text] [Related]
44. The complete amino acid sequence of a biologically active 197-residue fragment of M protein isolated from type 5 group A streptococci. Manjula BN; Acharya AS; Mische SM; Fairwell T; Fischetti VA J Biol Chem; 1984 Mar; 259(6):3686-93. PubMed ID: 6368549 [TBL] [Abstract][Full Text] [Related]
45. Repeating covalent structure of streptococcal M protein. Beachey EH; Seyer JM; Kang AH Proc Natl Acad Sci U S A; 1978 Jul; 75(7):3163-7. PubMed ID: 80011 [TBL] [Abstract][Full Text] [Related]
46. Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein. Dale JB; Seyer JM; Beachey EH J Exp Med; 1983 Nov; 158(5):1727-32. PubMed ID: 6195292 [TBL] [Abstract][Full Text] [Related]
47. Domain structure and molecular flexibility of streptococcal M protein in situ probed by limited proteolysis. Khandke KM; Fairwell T; Acharya AS; Manjula BN J Protein Chem; 1990 Oct; 9(5):511-22. PubMed ID: 2085376 [TBL] [Abstract][Full Text] [Related]
48. Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections. Dale JB; Chiang EC J Infect Dis; 1995 Apr; 171(4):1038-41. PubMed ID: 7706785 [TBL] [Abstract][Full Text] [Related]
49. Protective immunity evoked by synthetic peptides of streptococcal M proteins. Beachey EH Adv Exp Med Biol; 1985; 185():193-200. PubMed ID: 2416199 [No Abstract] [Full Text] [Related]
50. Mapping T-cell epitopes in group A streptococcal type 5 M protein. Robinson JH; Atherton MC; Goodacre JA; Pinkney M; Weightman H; Kehoe MA Infect Immun; 1991 Dec; 59(12):4324-31. PubMed ID: 1718873 [TBL] [Abstract][Full Text] [Related]
51. Group A streptococcal M proteins: virulence factors and protective antigens. Robinson JH; Kehoe MA Immunol Today; 1992 Sep; 13(9):362-7. PubMed ID: 1281632 [TBL] [Abstract][Full Text] [Related]
52. Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Pruksakorn S; Currie B; Brandt E; Martin D; Galbraith A; Phornphutkul C; Hunsakunachai S; Manmontri A; Good MF Lancet; 1994 Sep; 344(8923):639-42. PubMed ID: 7520963 [TBL] [Abstract][Full Text] [Related]
53. Complete amino acid sequence of streptococcal PepM49 protein, a nephritis-associated serotype. Conserved conformational design among sequentially distinct M protein serotypes. Khandke KM; Fairwell T; Acharya AS; Trus BL; Manjula BN J Biol Chem; 1988 Apr; 263(11):5075-82. PubMed ID: 2451662 [TBL] [Abstract][Full Text] [Related]
54. New protective antigen of group A streptococci. Dale JB; Chiang EY; Liu S; Courtney HS; Hasty DL J Clin Invest; 1999 May; 103(9):1261-8. PubMed ID: 10225969 [TBL] [Abstract][Full Text] [Related]
55. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Brandt ER; Hayman WA; Currie B; Carapetis J; Wood Y; Jackson DC; Cooper J; Melrose WD; Saul AJ; Good MF Immunology; 1996 Nov; 89(3):331-7. PubMed ID: 8958044 [TBL] [Abstract][Full Text] [Related]
56. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Brandt ER; Hayman WA; Currie B; Pruksakorn S; Good MF Vaccine; 1997 Nov; 15(16):1805-12. PubMed ID: 9364687 [TBL] [Abstract][Full Text] [Related]
57. Difference in the structural features of streptococcal M proteins from nephritogenic and rheumatogenic serotypes. Khandke KM; Fairwell T; Manjula BN J Exp Med; 1987 Jul; 166(1):151-62. PubMed ID: 3298523 [TBL] [Abstract][Full Text] [Related]
58. Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen. Beachey EH; Stollerman GH; Chiang EY; Chiang TM; Seyer JM; Kang AH J Exp Med; 1977 Jun; 145(6):1469-83. PubMed ID: 325168 [TBL] [Abstract][Full Text] [Related]
59. Separation of the type specific M protein from toxic cross reactive antigens of group A streptococci. Beachey EH; Chiang EY; Seyer JM; Kang AH; Chiang TM; Stollerman GH Trans Assoc Am Physicians; 1977; 90():390-400. PubMed ID: 347677 [No Abstract] [Full Text] [Related]
60. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Hayman WA; Toth I; Flinn N; Scanlon M; Good MF Immunol Cell Biol; 2002 Apr; 80(2):178-87. PubMed ID: 11940119 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]